Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
151 hedge funds and large institutions have $731M invested in Taro Pharmaceutical Industries Ltd. in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 30 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
7% less funds holding
Funds holding: 162 → 151 (-11)
12% less capital invested
Capital invested by funds: $831M → $731M (-$99.7M)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
57% less call options, than puts
Call options by funds: $358K | Put options by funds: $832K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.7M |
| 2 |
MICM
Matthews International Capital Management
San Francisco,
California
|
+$11.1M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.56M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$7.93M |
| 5 |
APG Asset Management
Amsterdam,
Netherlands
|
+$5.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$32M |
| 2 |
Goldman Sachs
New York
|
-$30.7M |
| 3 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$10M |
| 4 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$8.7M |
| 5 |
Renaissance Technologies
New York
|
-$8.62M |
TARO Hedge Fund Activity: Q4 2016 in Review
151 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2016, worth a combined $731M — down 12% from $831M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TARO and 23 opened new positions — a net loss of 7 holders — while 55 trimmed existing stakes and 58 added.
The largest buyer was Fidelity Investments, adding an estimated $15.7M. The largest seller was Acadian Asset Management, cutting an estimated $32M.
- 151 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2016, down from 162 in Q3 2016.
- Funds reported $731M of Taro Pharmaceutical Industries Ltd. stock for Q4 2016, down 12% quarter-over-quarter.
- 23 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2016 and 30 closed out, a net change of -7 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2016 was Fidelity Investments, an estimated $15.7M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2016 was Acadian Asset Management, an estimated $32M sold.
Based on aggregated 13F filings for Q4 2016.